A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or S

• Status: Completed
• Trial end date: 2003-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study looks at the healing rates in patients with Erosive Esophagitis (EE) when treated with either esomeprazole or lansoprazole

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Dexlansoprazole; Esomeprazole; Lansoprazole

Criteria

Inclusion Criteria:

• Episodes of heartburn (described as a burning feeling, rising from the stomach or lower part of the chest up towards the neck) for 2 days or more during the last 7 days prior to baseline.

• Confirmed Erosive Esophagitis within 1 week prior to starting the study.

Exclusion Criteria:

• Any signs of gastrointestinal bleeding at the time of the starting the study.

• Any previous gastric or esophageal surgery.

• Various gastrointestinal diseases as listed in the protocol.